DOCSLIB.ORG

Review Non-ABO Red Blood Cell Alloantibodies Following Allogeneic Hematopoietic Stem Cell Transplantation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Review Non-ABO Red Blood Cell Alloantibodies Following Allogeneic Hematopoietic Stem Cell Transplantation Bone Marrow Transplantation (2004) 33, 1169–1172 & 2004 Nature Publishing Group All rights reserved 0268-3369/04 $30.00 www.nature.com/bmt Review Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation M Franchini, G Gandini and G Aprili Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy Summary: and minor blood group incompatibility but, not rarely, more than one type of mechanism is involved.1 Immune-mediated hemolysis is a well-recognized occur- Alloimmune hemolytic anemia (AHA) following major rence which complicates the period following a bone and minor ABO-mismatched allogeneic hematopoietic stem marrow transplant (BMT). However, although many cell (HSC) transplantation is one of the most common and studies have investigated the hemolytic anemia following dangerous immunohematological complications of this ABO-incompatible BMT, data regarding the occurrence procedure.2 Less frequently, other RBC antigen systems, of alloantibodies against red blood cell (RBC) antigens in most cases those of the Rh system, have been implicated other than ABO in patients undergoing hematopoietic in the development of AHA.1 However, although the stem cell transplantation are limited. In this review, we hemolytic complications following ABO-incompatible briefly analyze the most important non-ABO red blood BMT have been investigated by several authors,2 only few cell (RBC) antigen systems involved in the development of reports, almost anecdotally, have described the immuno- post-BMT alloimmune hemolytic anemia, paying parti- hematological complications following non-ABO incompa- cular attention to the pathogenic mechanisms and the tible transplants. In this review, we briefly report the most clinical significance of the alloantibodies involved. Among important non-ABO RBC antigen systems implicated in the non-ABO RBC antigens, RhD antigen is the one most post transplant AHA and analyze their clinical significance. frequently implicated in the development of post-BMT alloimmune hemolytic anemia. Although less frequent than hemolysis following transplants with ABO incompat- ibility, non-ABO-incompatible allograft hemolysis may Incidence of non-ABO RBC alloantibodies after allogeneic severely complicate the post-BMT period creating difficult BMT clinical management issues. For this reason, we advise careful pre-transplant donor and recipient checks for the Only few data are available in the published literature on most important RBC antigen systems and close post- the frequency of non-ABO red cell alloimmunization in the BMT immunohematological monitoring in those patients post transplant setting.3–7 Ting et al3 described the undergoing allogeneic hematopoietic stem cell transplant production of non-ABO red cell alloantibodies in 13 of with RBC antigen incompatibility. 150 patients (8.7%) after BMT. However, examining the Bone Marrow Transplantation (2004) 33, 1169–1172. series carefully, only nine of the 150 (6%) had non-ABO doi:10.1038/sj.bmt.1704524 alloantibodies that had developed during the post-BMT Published online 19 April 2004 period. Abou-Elella et al4 found that two of 45 patients Keywords: hematopoietic stem cell transplantation; red (4.4%) who received an allogeneic BMT developed non- blood cells; alloantibodies; hemolysis ABO alloantibodies after the transplantation. De la Rubia et al5 recently reported a similar frequency (3.7%) in a series of 217 patients undergoing allogeneic hemopoietic Hemolysis is a well-recognized complication of allogeneic peripheral cell transplantation and also identified ABO bone marrow transplantation (BMT) and may be caused by incompatibility and patient’s age as the only two variables immune and nonimmune mechanisms. Post transplant significantly associated with the development of non-ABO immune-mediated hemolysis may be the result of auto- RBC alloantibodies. In a retrospective analysis of the blood immune effects, passenger lymphocyte syndrome, major bank records of 427 allogeneic HSC transplant recipients seen between 1994 and 1999, Young et al6 observed a very low incidence (nearly 1%) of post-BMT non-ABO/RhD red cell alloantibodies. If the incidence of such alloanti- bodies in the post-BMT period is low, the frequency with which they cause clinically significant immune hemolysis Correspondence: Dr M Franchini, Servizio di Immunoematologia e seems to be even much lower. In fact, Hows et al7 found Trasfusione, Ospedale Policlinico, 37134 Verona, Italy; E-mail: [email protected] that only one out of the four patients with post-BMT anti- Published online 19 April 2004 Rh alloantibodies developed clinical hemolysis. However, Non-ABO RBC alloantibodies and BMT M Franchini et al 1170 Table 1 Non-ABO red blood cell group antigen systems involved in the development of post-BMT alloimmune hemolytic anemia RBC antigen Antibodies Mechanism of hemolysis system Rh system Anti-D, -C, -c, -E Delayed hemolytic anemia,13,21,32 which may be severe after major Rh-mismatched grafts.15 Passenger lymphocyte syndrome7 and chronic hemolysis (in the case of persistence of mixed chimerism)8 have also been described Kell system Anti-Kell Delayed hemolytic anemia25,28 Kidd system Anti-JKa, -JKb Severe acute hemolytic anemia with intravascular hemolysis (passenger lymphocyte syndrome),6,29 delayed hemolytic anemia25 MNSs system Anti-M, -N, -S, -s Delayed hemolytic anemia6,25 Lewis system Anti-Lewisa, -Lewisb Passenger lymphocyte syndrome26 although rare, hemolytic episodes have often been de- patients undergoing BMT with incompatibilities involving scribed as severe.1,7 the RhD system should receive prophylaxis with infusion of Table 1 summarizes the most important non-ABO RBC Rh-negative blood or anti-RhD immunoglobulins. An anti- group antigen systems involved in the development of RhD antibody does not necessarily pre-exist, since it may clinically significant post-BMT alloimmune hemolytic be produced during the BMT due to the mismatch between anemia. the donor and recipient. A RhD-positive bone marrow recipient may develop anti-RhD antibodies following transplant if the donor is RhD negative. The recipient’s Incompatibility involving the Rh system residual RBC (RhD positive) may be sufficiently numerous to stimulate the donor’s engrafted lymphocytes.1 However, Among the non-ABO red cell antigen systems, the Rh this event occurs only rarely since the donor-related system is the one most frequently implicated in the primary immune response usually starts about 6 months development of post transplant AHA.1,8 Mismatching of after BMT and after this period, if recipient bone marrow is the Rh system has different features from ABO mis- 100% of donor origin, residual RhD-positive recipient matches.9 In fact, as the anti-Rh alloantibody does not RBC are no longer detectable.19 It is also unlikely that the occur naturally, we consider a major or minor Rh reverse situation (RhD-negative recipient and RhD-posi- incompatibility only when either the recipient or the donor tive donor) may develop a de novo anti-RhD antibody, has antibodies following a previous exposure (eg pregnancy since the recipient lymphocytes (the only cells capable of and/or transfusions). Although bone marrow transplants producing anti-RhD antibody) are destroyed by the with Rh incompatibility involving C, c and E antigens have conditioning treatment. However, if mixed erythrocyte been described in the medical literature,7,10,11 most reports chimerism persists after the BMT, severe hemolytic anemia regard the D antigen.12–16 Like ABO incompatibility, RhD due to the development of autoantibodies with donor– incompatibility can cause hemolytic anemia after BMT.9 A antirecipient specificities for non-ABO system RBC anti- major RhD incompatibility between donor and recipient of gens may complicate the post transplant period.8 Another a BMT may lead to a severe delayed hemolytic anemia.15 occurrence in the BMT setting is alloimmunization, in Panhypoplasia was observed in a patient following a major patients receiving RhD-negative bone marrow transplants, RhD incompatible BMT with marrow recovery after the against platelet concentrates from RhD-positive donors. subsequent spontaneous reduction in the anti-RhD titer.17 This event seems to be not uncommon: the incidence of A minor RhD incompatibility can cause both immediate anti-RhD antibodies in oncohematologic patients who and delayed hemolysis, the former being due to anti-RhD underwent autologous BMT and received platelet transfu- alloantibodies produced by lymphocytes infused with the sions seems to be nearly 20%.20 For this reason, some donor marrow (passenger lymphocyte syndrome) and the authors suggest prophylaxis with intravenous anti-RhD latter being due to anti-RhD alloantibodies produced by immunoglobulins during platelet transfusions in such donor engrafted lymphocytes.7 A simultaneous mismatch patients in order to prevent alloimmunization against involving both ABO and Rh systems can also occur and RhD.21 Conversely, other authors found a low incidence may cause hemolysis and/or pure red cell aplasia in the post of anti-D alloimmunization in hematologic patients receiv- transplant period.7,18 RhD incompatibility is treated in the ing D-incompatible platelet transfusions.22–24 same way as ABO incompatibility, in order to prevent post A BMT recipient with a pre-existing anti-RhD alloanti- transplant hemolysis.9 Thus, in the case of RhD major body must be transfused with RhD-negative RBC until the incompatibility
Load more

Recommended publications
  • The Membrane Complement Regulatory Protein CD59 and Its Association with Rheumatoid Arthritis and Systemic Lupus Erythematosus
    Current Medicine Research and Practice 9 (2019) 182e188 Contents lists available at ScienceDirect Current Medicine Research and Practice journal homepage: www.elsevier.com/locate/cmrp Review Article The membrane complement regulatory protein CD59 and its association with rheumatoid arthritis and systemic lupus erythematosus * Nibhriti Das a, Devyani Anand a, Bintili Biswas b, Deepa Kumari c, Monika Gandhi c, a Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India b Department of Zoology, Ramjas College, University of Delhi, India c University School of Biotechnology, Guru Gobind Singh Indraprastha University, India article info abstract Article history: The complement cascade consisting of about 50 soluble and cell surface proteins is activated in auto- Received 8 May 2019 immune inflammatory disorders. This contributes to the pathological manifestations in these diseases. In Accepted 30 July 2019 normal health, the soluble and membrane complement regulatory proteins protect the host against Available online 5 August 2019 complement-mediated self-tissue injury by controlling the extent of complement activation within the desired limits for the host's benefit. CD59 is a membrane complement regulatory protein that inhibits the Keywords: formation of the terminal complement complex or membrane attack complex (C5b6789n) which is CD59 generated on complement activation by any of the three pathways, namely, the classical, alternative, and RA SLE the mannose-binding lectin pathway. Animal experiments and human studies have suggested impor- Pathophysiology tance of membrane complement proteins including CD59 in the pathophysiology of rheumatoid arthritis Disease marker (RA) and systemic lupus erythematosus (SLE). Here is a brief review on CD59 and its distribution, structure, functions, and association with RA and SLE starting with a brief introduction on the com- plement system, its activation, the biological functions, and relations of membrane complement regu- latory proteins, especially CD59, with RA and SLE.
    [Show full text]
  • ABH Secretor and Lewis Subtype Status Peter J
    Metabolic and Immunologic Consequences of ABH Secretor and Lewis Subtype Status Peter J. D’Adamo, ND, and Gregory S. Kelly, ND Abstract Determining ABH secretor phenotype and/or Lewis (Le) blood group status can be useful to the metabolically-oriented clinician. For example, differences in ABH secretor status drastically alter the carbohydrates present in body fluids and secretions; this can have profound influence on microbial attachment and persistence. Lewis typing is one genetic marker which might help identify subpopulations of individuals genetically prone to insulin resistance, autoimmunity, and heart disease. Understanding the clinical significance of ABH secretor status and the Lewis blood groups can provide insight into seemingly unrelated aspects of physiology, including variations in intestinal alkaline phosphatase activity, propensities toward blood clotting, reliability of some tumor markers, the composition of breast milk, and several generalized aspects of the immune function. Since the relevance of ABH blood group antigens as tumor markers and parasitic/bacterial/viral receptors and their association with immunologically important proteins is now well established, the prime biologic role for ABH blood group antigens may well be independent and unrelated to the erythrocyte. (Altern Med Rev 2001;6(4):390-405) Functional and Genetic Factors Involved in ABH Secretion The term “ABH secretor,” as used in blood banking, refers to secretion of ABO blood group antigens in fluids such as saliva, sweat, tears, semen, and serum. A person who is an ABH secretor will secrete antigens according to their blood group; for example, a group O individual will secrete H antigen, a group A individual will secrete A and H antigens, etc.
    [Show full text]
  • New Methods for Characterization of N-Type Glycosylation of Proteins by Integration of LC-MS/MS and NMR
    New Methods for Characterization of N-type Glycosylation of Proteins by Integration of LC-MS/MS and NMR Thesis Submitted in fulfillment of the requirements of the degree Doctor rer. nat. at the Department of Chemistry, Faculty of Sciences, University of Hamburg by Alena Wiegandt from Hamburg Hamburg, 2016 This thesis was prepared at the Institute for Organic Chemistry from October 2012 to July 2016 (managing director: Prof. Dr. C.B.W. Stark). I would like to thank Prof. Dr. Bernd Meyer for his continuous and motivating support during the work on my PhD thesis. I would like to thank Prof. Dr. Dr. h. c. mult. Wittko Francke for being the second reviewer of this thesis. 1st Reviewer: Prof. Dr. Bernd Meyer 2nd Reviewer: Prof. Dr. Dr. h.c. mult. Wittko Francke Date of defense: 07.04.2017 OUTLINE Outline ABBREVIATIONS ..................................................................................................................... VIII 1 SUMMARY ............................................................................................................................ 1 2 ZUSAMMENFASSUNG .......................................................................................................... 4 3 INTRODUCTION ................................................................................................................... 7 3.1 Glycosylation of Proteins - Biosynthesis, Structures, Functions .................................... 8 3.2 Glycans in Human Diseases .........................................................................................
    [Show full text]
  • Blood Group Have Increased Susceptibility to Symptomatic \(Vibrio\) \(Cholerae\) O1 Infection
    Individuals with Le(a+b−) Blood Group have Increased Susceptibility to Symptomatic \(Vibrio\) \(cholerae\) O1 Infection The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Arifuzzaman, Mohammad, Tanvir Ahmed, Mohammad Arif Rahman, Fahima Chowdhury, Rasheduzzaman Rashu, Ashraful I. Khan, Regina C. LaRocque, et al. 2011. Individuals with Le(a+b−) blood group have increased susceptibility to symptomatic \(Vibrio\) \(cholerae\) O1 infection. PLoS Neglected Tropical Diseases 5(12): e1413. Published Version doi:10.1371/journal.pntd.0001413 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:9369412 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Individuals with Le(a+b2) Blood Group Have Increased Susceptibility to Symptomatic Vibrio cholerae O1 Infection Mohammad Arifuzzaman1,2, Tanvir Ahmed1, Mohammad Arif Rahman1, Fahima Chowdhury1, Rasheduzzaman Rashu1, Ashraful I. Khan1, Regina C. LaRocque2,3, Jason B. Harris2,4, Taufiqur Rahman Bhuiyan1, Edward T. Ryan2,3,5, Stephen B. Calderwood2,3,6., Firdausi Qadri1*. 1 Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research Bangladesh (ICDDR,B), Dhaka, Bangladesh, 2 Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America,
    [Show full text]
  • SPECIFICATION SPN214/4 the Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion Copy Numb
    SPECIFICATION SPN214/4 The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion This Specification replaces Copy Number SPN214/3 Effective 03/05/17 Summary of Significant Changes Change of author to Nicole Thornton from Geoff Daniels (retired). Update to blood group systems (new systems added) Update to some rare antibodies due to availability of new data Change of regional coordinators and associated contact information Removal of unnecessary information to improve clarity Purpose This document outlines current knowledge on the clinical significance of blood group alloantibodies. Its prime purpose is to enable clinical decisions to be made regarding the management and blood transfusion support of patients with blood group antibodies that are not commonly encountered and for which antigen-negative blood is not available in the routine stock. The overall aim is to ensure that a uniform RCI Clinical Policy for the supply of blood for transfusion is implemented throughout the NHSBT. Definitions BSH British Committee for Standards in IAT Indirect Antiglobulin Test Haematology IBGRL International Blood Group DHTR Delayed Haemolytic Transfusion Reference Laboratory Reaction IRDP International Rare Donor Panel HDFN Haemolytic Disease of the Fetus NHSBT NHS Blood and Transplant and Newborn NFBB National Frozen Blood Bank HTR Haemolytic Transfusion Reaction RCI Red Cell Immunohaematology Applicable Documents ESD121 Guidelines for pre-transfusion INF1302: HGP project – targets, phenotype compatibility procedures
    [Show full text]
  • Actinomyces Adenosine Diphosphate Adenylate
    Volume 192, Supplement FEBS LETTERS December 1985 ACTINOMYCES The status of Y,, and maintenance energy as biologically in- See: MICROORGANISMS terpretable phenomena Tempest D W & Neijssel 0 M (1984) Annu. Rev. Microbial. 38,459 ADENOSINE DIPHOSPHATE Phosphoenolpyruvate-pyruvate metabolism in bivalve mol- lusts Zwaan A de & Dando P R (1984) Mol. Physiol. 5,285 Involvement of poly(ADP-ribose) in the radtation response of mammalian cells Ben-Hur E (1984) Int. .I. Radiat. Biol. 46,659 ADENYLATE CYCLASE ADP-ribose in DNA repair - a new component of DNA ex- See. ENZYMES AND ENZYME REGULATION cision repair Shall S (1984) Advan. Radmt. Btol. 11, 1 ADIPOSE TISSUE ADENOSINE MONOPHOSPHATE Regulation of adipose tissue lipolysis through reversible phosphorylatton of hormone-sensitive lipase Effects of cyclic adenosine 3’,5’-monophosphate and calcium Belfrage P. Fredrikson G. Olsson H & Stralfors P (1984) on cellular function and growth of mast cells [In Japanese; Advan. Cyclic Nucl. Prot. Phosph. Res. 17, 351 English abstract] Ichikawa A (1984) Yakugaku Zusshi, 104, 1109 Adipose tissue glycogen synthesis [Mmireview] Eichner R D (1984) ht. J. Biochem. 16,257 The role of cyclic AMP m insulin release Malaisse W J & Malaisse-Lagae F (1984) Experientiu, 40, Modulatton of adipose tissue fat composition by diet: a review 1068 Field C J & Clandinin M T (1984) Nutr. Res. 4,743 Multiple roles of ATP in the regulation of sugar transport in muscle and adipose tissue ADENOSINE TRIPHOSPHATE Gould M K (1984) Trends Biochem. Sci. 9, 524-527 Brown adipose tissue thermogenesis: mechanisms of control Electrophysiologic effects of adenosine triphosphate and aden- and relation to energy balance and obesity [Minisymposium] osine on the mammahan heart: clinical and experimental as- Himms-Hagen J & others (1984) Can.
    [Show full text]
  • Blood Group Antigen Lewis B Antibody - with BSA and Azide Mouse Monoclonal Antibody [Clone SPM194 ] Catalog # AH11267
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Blood Group Antigen Lewis B Antibody - With BSA and Azide Mouse Monoclonal Antibody [Clone SPM194 ] Catalog # AH11267 Specification Blood Group Antigen Lewis B Antibody - Blood Group Antigen Lewis B Antibody - With With BSA and Azide - Background BSA and Azide - Product Information The Lewis histo-blood group system comprises Application ,2,3, a set of fucosylated glycosphingolipids that are Primary Accession P21217 synthesized by exocrine epithelial cells and Other Accession 2525, 169238 circulate in body fluids. The glycosphingolipids Reactivity Human, Guinea function in embryogenesis, tissue Pig differentiation, tumor metastasis, Host Mouse inflammation, and bacterial adhesion. They are Clonality Monoclonal secondarily absorbed to red blood cells giving Isotype Mouse / IgG1, rise to their Lewis phenotype. This gene is a kappa member of the fucosyltransferase family, Calculated MW 45kDa KDa which catalyzes the addition of fucose to precursor polysaccharides in the last step of Blood Group Antigen Lewis B Antibody - With Lewis antigen biosynthesis. It encodes an BSA and Azide - Additional Information enzyme with alpha(1,3)-fucosyltransferase and alpha(1,4)-fucosyltransferase activities. Lewis Gene ID 2525 blood group antigens are carbohydrate moieties structurally integrated in mucous Other Names secretions. Lewis antigen system alterations Galactoside 3(4)-L-fucosyltransferase, have been described in gastric carcinoma and 2.4.1.65, Blood group Lewis associated lesions. Anomalous expression of alpha-4-fucosyltransferase, Lewis FT, Lewis B antigen has been found in some Fucosyltransferase 3, Fucosyltransferase III, non-secretory gastric carcinomas and FucT-III, FUT3, FT3B, LE colorectal cancers.
    [Show full text]
  • Blood Type Biochemistry and Human Disease By
    Blood Type Biochemistry and Human Disease By: D. Rose Ewald and Susan C.J. Sumner This is the peer reviewed version of the following article: D. Rose Ewald & Susan C.J. Sumner. (2016). Blood Type Biochemistry and Human Disease. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 8(6), 517-535. doi:10.1002/wsbm.1355 which has been published in final form at https://doi.org/10.1002/wsbm.1355. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. ***© 2016 Wiley Periodicals, Inc. Reprinted with permission. No further reproduction is authorized without written permission from Wiley. This version of the document is not the version of record. *** Abstract: Associations between blood type and disease have been studied since the early 1900s when researchers determined that antibodies and antigens are inherited. In the 1950s, the chemical identification of the carbohydrate structure of surface antigens led to the understanding of biosynthetic pathways. The blood type is defined by oligosaccharide structures, which are specific to the antigens, thus, blood group antigens are secondary gene products, while the primary gene products are various glycosyltransferase enzymes that attach the sugar molecules to the oligosaccharide chain. Blood group antigens are found on red blood cells, platelets, leukocytes, plasma proteins, certain tissues, and various cell surface enzymes, and also exist in soluble form in body secretions such as breast milk, seminal fluid, saliva, sweat, gastric secretions, urine, and amniotic fluid. Recent advances in technology, biochemistry, and genetics have clarified the functional classifications of human blood group antigens, the structure of the A, B, H, and Lewis determinants and the enzymes that produce them, and the association of blood group antigens with disease risks.
    [Show full text]
  • Immunohematology
    Immunohematology Journal of Blood Group Serology and Education Celebrating 2 Ye5ars Volume 25, Number 3, 2009 Immunohematology Journal of Blood Group Serology and Education Volume 25, Number 3, 2009 Contents Letter to the Readers 89 Introduction to Vol. 25, No. 3, of Immunohematology J.P. AuBuchon Invited Review: Milestones Series 90 Pioneers of blood group serology in the United States: 1950–1990 S.R. Pierce Review 95 MNS blood group system: a review M.E. Reid Review 102 Quality activities associated with hospital tissue services C.M. Hillberry and A.J. Schlueter Review 107 Logistical aspects of human surgical tissue management in a hospital setting B.M. Alden and A.J. Schlueter Review 112 Lewis blood group system review M.R. Combs Review 119 Recognition and management of antibodies to human platelet antigens in platelet transfusion–refractory patients R.R. Vassallo Review 125 Detection and identification of platelet antibodies and antigens in the clinical laboratory B.R. Curtis and J.G. McFarland Review 136 Investigating the possibility of drug-dependent platelet antibodies J.P. AuBuchon and M.F. Leach 141 Announcements 142 Advertisements 146 Instructions for Authors Editors-in-Chief Managing Editor Sandra Nance, MS, MT(ASCP)SBB Cynthia Flickinger, MT(ASCP)SBB Philadelphia, Pennsylvania Philadelphia, Pennsylvania Connie M. Westhoff, PhD, MT(ASCP)SBB Technical Editors Philadelphia, Pennsylvania Christine Lomas-Francis, MSc New York City, New York Senior Medical Editor Geralyn M. Meny, MD Dawn M. Rumsey, ART(CSMLT) Philadelphia, Pennsylvania Glen Allen, Virginia Associate Medical Editors David Moolten, MD Ralph R. Vassallo, MD Philadelphia, Pennsylvania Philadelphia, Pennsylvania Editorial Board Patricia Arndt, MT(ASCP)SBB Brenda J.
    [Show full text]
  • International – Molecular Pathology Catalog 2020
    Catalog 2020 (International) Doc. No. 937-4096.0 Rev D 2020 Dear Customer, We are pleased to present the BioGenex Molecular Pathology Catalog. As a vertically integrated company, we develop, manufacture and market highly innovative and fully automated systems for cancer diagnosis, prognosis and therapy selection. Xmatrx® systems redefine complete automation for the molecular pathology laboratory and standardize the protocol from baking through final cover-slipping in three simple steps - Load, Click and View. Compared to any other system on the market, Xmatrx® systems offer clean intense stain(s), automate more assay steps, and enable automation of technologies for the future molecular pathology laboratory. • Xmatrx® ELITE integrates All-in-One staining of IHC, ISH, special stains and beyond • Xmatrx® Infinity is a high-performance staining platform for life sciences and translational research • Xmatrx® ULTRA Dx is the next-generation system with new features such as Auto Drain, Auto DAB mixing and with new technologies • Xmatrx® ULTRA Rx is the next-generation system with new features and technologies for life sciences and translation research • NanoMtrx® 300 is a fully-automated, 30-slide benchtop compact system with micro-chamber® for IHC and ISH • NanoMtrx® 100 is a fully-automated, 10-slide benchtop compact system with micro-chamber® for IHC and ISH • NanoVIP® is a ten-slide automated system specifically designed for FISH • Xmatrx® MINI enables in situ PCR and nucleic acid hybridization with tools for building micro-chamber We also offer a series of i6000TM systems with very high throughput: 200 slides in an 8-hour shift. To maintain our tradition of offering superior solutions for the emerging needs of your laboratory, we offer a broad range of molecular pathology products for IHC, ISH, miRNA, multiplex and special staining of tissues including 400+ primary antibodies, molecular probes, detection systems, and ancillaries.
    [Show full text]
  • Do Blood Group Antigens and the Red Cell Membrane Influence Human
    cells Review Do Blood Group Antigens and the Red Cell Membrane Influence Human Immunodeficiency Virus Infection? Glenda M. Davison 1,2,* , Heather L. Hendrickse 1 and Tandi E. Matsha 1 1 SAMRC/CPUT/Cardiometabolic Health Research Unit, Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, P.O. Box 1906, Bellville 7530, South Africa; [email protected] (H.L.H.); [email protected] (T.E.M.) 2 Division of Haematology, Faculty of Health Science, University of Cape Town, Cape Town 7925, South Africa * Correspondence: [email protected]; Tel.: +27-21-959-6562; Fax: +27-21-959-6760 Received: 26 January 2020; Accepted: 26 March 2020; Published: 31 March 2020 Abstract: The expression of blood group antigens varies across human populations and geographical regions due to natural selection and the influence of environment factors and disease. The red cell membrane is host to numerous surface antigens which are able to influence susceptibility to disease, by acting as receptors for pathogens, or by influencing the immune response. Investigations have shown that Human Immunodeficiency Virus (HIV) can bind and gain entry into erythrocytes, and therefore it is hypothesized that blood groups could play a role in this process. The ABO blood group has been well studied. However, its role in HIV susceptibility remains controversial, while other blood group antigens, and the secretor status of individuals, have been implicated. The Duffy antigen is a chemokine receptor that is important in the inflammatory response. Those who lack this antigen, and type as Duffy null, could therefore be susceptible to HIV infection, especially if associated with neutropenia.
    [Show full text]
  • Clinical Significance of Antibodies to Antigens in the ABO, MNS, P1PK, Rh, Lutheran, Kell, Lewis, Duffy, Kidd, Diego, Yt, and Xg Blood Group Systems
    R EVIEW Proceedings from the International Society of Blood Transfusion Working Party on Immunohaematology, Workshop on the Clinical Significance of Red Blood Cell Alloantibodies, September 9, 2016, Dubai Clinical significance of antibodies to antigens in the ABO, MNS, P1PK, Rh, Lutheran, Kell, Lewis, Duffy, Kidd, Diego, Yt, and Xg blood group systems N.M. Thornton and S.P. Grimsley This report is part of a series reporting the proceedings from the ABO Blood Group System International Society of Blood Transfusion (ISBT) Working Party on Immunohaematology Workshop on the Clinical Significance The ABO blood group system was the first to be of Red Blood Cell Alloantibodies. The aim of the workshop was to review information regarding the clinical significance discovered and is still the most clinically important. Despite of alloantibodies to red blood cell antigens recognized by the consisting of just four polymorphic antigens—A, B, A,B, and ISBT. The first 12 systems will be covered in this report. A1—the genetics and carbohydrate chemistry underpinning It is understandable that many of the most clinically important 6 antibodies are directed toward antigens found in the blood the expression of these antigens is complex. Because these group systems discovered earlier in history. The ABO system was antigens are abundant on RBCs and because most adults have the first to be discovered and remains the most clinically “naturally occurring” antibodies to the antigens that they lack, important regarding transfusion. Immunohematology 2019; ABO antibodies are clinically significant; anti-A, -B, and -A,B 35:95–101. cause severe intravascular hemolytic transfusion reactions Key Words: clinical significance, red blood cell alloantibodies, (HTRs).
    [Show full text]